Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists01:30

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

571
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
571
Long-term Depression01:05

Long-term Depression

33.2K
Long-term depression, or LTD, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTD is the process of synaptic weakening that occurs over time between pre and postsynaptic neuronal connections. The synaptic weakening of LTD works in opposition to synaptic strengthening by long-term potentiation (LTP) and together are the main mechanisms that underlie learning and memory.
33.2K
Long-term Depression01:03

Long-term Depression

3.1K
Long-term depression, or LTD, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTD is the process of synaptic weakening that occurs over time between pre and postsynaptic neuronal connections. The synaptic weakening of LTD works in opposition to synaptic strengthening by long-term potentiation (LTP) and together are the main mechanisms that underlie learning and memory.
Calcium Ion Concentration Mechanism
If over...
3.1K
Freezing Point Depression and Boiling Point Elevation03:12

Freezing Point Depression and Boiling Point Elevation

39.6K
Boiling Point Elevation
The boiling point of a liquid is the temperature at which its vapor pressure is equal to ambient atmospheric pressure. Since the vapor pressure of a solution is lowered due to the presence of nonvolatile solutes, it stands to reason that the solution’s boiling point will subsequently be increased. Vapor pressure increases with temperature, and so a solution will require a higher temperature than will pure solvent to achieve any given vapor pressure, including one...
39.6K
Depressants01:28

Depressants

385
Depressant drugs, including alcohol and sedative-hypnotics, diminish central nervous system activity by enhancing the action of gamma-aminobutyric acid (GABA), a neurotransmitter that reduces brain activity and promotes relaxation. These substances can have various therapeutic uses but also pose significant risks, especially when misused or combined.
Alcohol is a common depressant that can induce a sense of relaxation and reduced inhibition at low doses. Contrary to its occasional...
385
Depression: Overview01:18

Depression: Overview

809
Depression is a prevalent mental illness marked by persistent sadness and lack of interest in previously enjoyable activities. It can take several forms, including major depression, persistent depressive disorder, and bipolar I and II disorders. Symptoms range from emotional changes like chronic worry to physical changes like sleep disturbances and suicidal thoughts. From a neurobiological perspective, depression is believed to be triggered by abnormalities in the brain's prefrontal cortex,...
809

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Novel 3-Methoxypropanamide Derivatives as Potential Antiseizure and Antinociceptive Agents: Experimental Evidence from In Vitro and In Vivo Studies.

Journal of medicinal chemistry·2026
Same author

Corrigendum to Combined olfactory bulbectomy and zinc deficiency induce complex neurobiological alterations resistant to classical antidepressant treatments: Insights from proteomic and neurochemical analyses' [Progress in Neuro-Psychopharmacology and Biological Psychiatry 145 (2026) 111643].

Progress in neuro-psychopharmacology & biological psychiatry·2026
Same author

Combined olfactory bulbectomy and zinc deficiency induce complex neurobiological alterations resistant to classical antidepressant treatments: Insights from proteomic and neurochemical analyses.

Progress in neuro-psychopharmacology & biological psychiatry·2026
Same author

Chronic 5-HT7R activation drives depressive phenotypes and synaptic dysfunction.

Acta pharmacologica Sinica·2026
Same author

Zinc, copper, and magnesium in premenstrual disorders: a narrative review.

Pharmacological reports : PR·2025
Same author

Asiatic acid potentiates the activity of common antidepressant drugs in mice.

Psychopharmacology·2025

Related Experiment Video

Updated: Jan 21, 2026

Examination of Anatomical Features of Retinal Ganglion Cells Under N-methyl-D-aspartic Acid (NMDA)-induced Excitotoxicity
07:11

Examination of Anatomical Features of Retinal Ganglion Cells Under N-methyl-D-aspartic Acid (NMDA)-induced Excitotoxicity

Published on: September 19, 2025

1.1K

An update on NMDA antagonists in depression.

Bartłomiej Pochwat1, Gabriel Nowak1, Bernadeta Szewczyk1

  • 1Maj Institute of Pharmacology, Polish Academy of Sciences, Laboratory of Trace Elements Neurobiology , Krakow , Poland.

Expert Review of Neurotherapeutics
|July 23, 2019
PubMed
Summary

New research on N-methyl-D-aspartate (NMDA) receptor antagonists shows promise for treating major depressive disorder (MDD). Esketamine

Keywords:
NMDA receptorantagonistantidepressantdepressionketamine

More Related Videos

A High-throughput Calcium-flux Assay to Study NMDA-receptors with Sensitivity to Glycine/D-serine and Glutamate
04:48

A High-throughput Calcium-flux Assay to Study NMDA-receptors with Sensitivity to Glycine/D-serine and Glutamate

Published on: July 10, 2018

9.8K
Application of a NMDA Receptor Conductance in Rat Midbrain Dopaminergic Neurons Using the Dynamic Clamp Technique
06:42

Application of a NMDA Receptor Conductance in Rat Midbrain Dopaminergic Neurons Using the Dynamic Clamp Technique

Published on: December 21, 2010

12.5K

Related Experiment Videos

Last Updated: Jan 21, 2026

Examination of Anatomical Features of Retinal Ganglion Cells Under N-methyl-D-aspartic Acid (NMDA)-induced Excitotoxicity
07:11

Examination of Anatomical Features of Retinal Ganglion Cells Under N-methyl-D-aspartic Acid (NMDA)-induced Excitotoxicity

Published on: September 19, 2025

1.1K
A High-throughput Calcium-flux Assay to Study NMDA-receptors with Sensitivity to Glycine/D-serine and Glutamate
04:48

A High-throughput Calcium-flux Assay to Study NMDA-receptors with Sensitivity to Glycine/D-serine and Glutamate

Published on: July 10, 2018

9.8K
Application of a NMDA Receptor Conductance in Rat Midbrain Dopaminergic Neurons Using the Dynamic Clamp Technique
06:42

Application of a NMDA Receptor Conductance in Rat Midbrain Dopaminergic Neurons Using the Dynamic Clamp Technique

Published on: December 21, 2010

12.5K

Area of Science:

  • Neuroscience and Pharmacology
  • Psychiatry

Background:

  • Current antidepressants have limited efficacy and slow action.
  • The N-methyl-D-aspartate (NMDA) receptor is a key target for novel antidepressant development.
  • There is a continuous need for improved treatments for major depressive disorder (MDD).

Purpose of the Study:

  • To review preclinical data on the antidepressant efficacy and mechanisms of NMDA antagonists.
  • To update on the clinical efficacy of ketamine, esketamine, and other NMDA receptor antagonists.

Main Methods:

  • Systematic review of published preclinical studies on NMDA antagonists.
  • Analysis of published clinical trial results for ketamine, esketamine, and other NMDA antagonists.

Main Results:

  • Preclinical data support the antidepressant potential of various NMDA antagonists.
  • Clinical studies demonstrate the efficacy of ketamine and esketamine in treating MDD.
  • Recent findings highlight unresolved issues regarding the clinical use of NMDA receptor antagonists.

Conclusions:

  • The FDA approval of esketamine marks a significant advancement in NMDA receptor-targeted antidepressant research.
  • NMDA receptor antagonists offer hope for treatment-resistant depression.
  • Further research is needed to clarify the optimal use and address safety concerns of NMDA receptor antagonists.